Non-small cell lung carcinoma (NSCLC) cases with next-generation sequencing proven ERBB2 point mutations (n=8) or amplifications (n=11) were assessed with commercially available ERBB2 (HER2) immunohistochemical antibodies. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.